Beijing Capital International Airport (HKG:0694) issued the first tranche of its 2026 short-term debentures, raising 1 billion yuan, according to a Wednesday Hong Kong bourse filing.
The one-year notes carry an interest rate of 1.37%, with interest accruing from June 3 and redemption due on June 3, 2027.
Shares of the airport operator were down nearly 2% in Thursday morning trade.
Immutep (ASX:IMM) said a first-in-human phase one study evaluating IMP761, a potential therapeutic option for autoimmune diseases, met its primary endpoint, showing favorable safety and tolerability in healthy volunteers in the single ascending dose part of the study, according to a Thursday filing with the Australian bourse.IMP761 was designed to target activated T cells at inflammation sites to reduce pathological immune responses while preserving systemic immune function, the filing said.Early findings showed "significant and clinically relevant" pharmacodynamic activity, including the reduction of local inflammatory responses and attenuated T-cell activity compared with placebo across groups ranging from 0.9 milligrams per kilogram to 7 milligrams per kilogram, per the filing.Shares fell nearly 4% in morning trade Thursday.
Hansoh Pharmaceutical (HKG:3692) said China's National Medical Products Administration accepted its application of olatorepatide injection to treat obesity, according to a Thursday filing with the Hong Kong bourse.The drug is meant to be administered once a week.Shares of the company fell nearly 1% in recent morning trade.
Qantas Airways' (ASX:QAN) market share trends in Australia overall remain stable at 49%, Jarden said in a Thursday note.Overall, the Australian market is expected to see a snap back in scheduled seats growth through July, up 11% year-over-year, driven largely by a scheduled uplift in seats capacity from Asian discounters and Chinese carriers.Deep capacity reductions for Middle East carriers, which fell 71% through April, but are set to recover over the course of the first half of fiscal year 2027, and restore capacity by June to pre-conflict levels. North American seat growth has remained resilient over the final few months of the second half of fiscal year 2026, based on current scheduled capacity.Based on Visible Alpha consensus estimates, Qantas' international capacity growth is forecast at 2.1% in the first half of fiscal year 2027.The investment firm retained its buy rating and its AU$11.25 per share price target on Qantas.